Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
Taiwan
· Delayed Price · Currency is TWD 32.50
+0.85 (2.69%)
Mar 10, 2026, 1:59 PM CST
TPEX:7427 Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Net Income | -87.75 | -104.92 | -61 | -67.13 | -35.86 | -31.27 | Upgrade
|
| Depreciation & Amortization | 7.67 | 6.9 | 4.28 | 1.76 | 1.44 | 0.98 | Upgrade
|
| Other Amortization | 0.05 | 0.04 | 0.07 | 0.06 | 0.06 | 0.06 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | - | -0.12 | - | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | - | - | - | 2.57 | Upgrade
|
| Stock-Based Compensation | 8.48 | 14.97 | 11.29 | 4.91 | 3.66 | 1.21 | Upgrade
|
| Other Operating Activities | 0.11 | 0.13 | 0.09 | -0.01 | -0.03 | - | Upgrade
|
| Change in Accounts Receivable | 0.12 | -0.62 | -0.09 | - | -0.04 | 0.09 | Upgrade
|
| Change in Inventory | 0.2 | 3.15 | -6.16 | - | - | 0.02 | Upgrade
|
| Change in Accounts Payable | -0.3 | 6.61 | 1.05 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -8.14 | -3.09 | -4.4 | -16.76 | -3.15 | -15.54 | Upgrade
|
| Operating Cash Flow | -79.56 | -76.85 | -54.99 | -77.17 | -33.92 | -41.88 | Upgrade
|
| Capital Expenditures | -0.1 | -2.11 | -2.93 | -0.05 | -0.04 | -0.02 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.12 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1.08 | -1.36 | -16.29 | -1.18 | -27.97 | -13.05 | Upgrade
|
| Investment in Securities | -45 | -130.7 | -160.5 | -74.19 | -62.32 | 13.5 | Upgrade
|
| Other Investing Activities | -0.12 | 0.68 | -3.18 | -2.45 | - | - | Upgrade
|
| Investing Cash Flow | -46.29 | -133.49 | -182.78 | -77.85 | -90.32 | 0.43 | Upgrade
|
| Long-Term Debt Repaid | - | -3 | -1.25 | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -3 | -3 | -1.25 | - | - | - | Upgrade
|
| Issuance of Common Stock | 2.22 | 188.84 | 307.49 | 203.31 | 120 | 83.6 | Upgrade
|
| Financing Cash Flow | -30.75 | 185.84 | 306.24 | 203.31 | 120 | 83.6 | Upgrade
|
| Net Cash Flow | -156.61 | -24.49 | 68.47 | 48.29 | -4.24 | 42.15 | Upgrade
|
| Free Cash Flow | -79.66 | -78.96 | -57.92 | -77.21 | -33.96 | -41.9 | Upgrade
|
| Free Cash Flow Margin | -4472.71% | -4685.82% | -1194.21% | -14298.70% | -5389.68% | - | Upgrade
|
| Free Cash Flow Per Share | -1.83 | -1.92 | -1.60 | -3.20 | -1.61 | -2.65 | Upgrade
|
| Cash Interest Paid | - | - | - | - | - | 0.02 | Upgrade
|
| Levered Free Cash Flow | -55.65 | -53.21 | -48.79 | -50.61 | -29.53 | -39.85 | Upgrade
|
| Unlevered Free Cash Flow | -55.57 | -53.14 | -48.73 | -50.61 | -29.53 | -39.84 | Upgrade
|
| Change in Working Capital | -8.12 | 6.04 | -9.6 | -16.76 | -3.19 | -15.43 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.